Catalyst Capital Advisors LLC Makes New $101,000 Investment in IQVIA Holdings Inc. (NYSE:IQV)

Catalyst Capital Advisors LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 425 shares of the medical research company’s stock, valued at approximately $101,000.

A number of other hedge funds also recently modified their holdings of the business. Impax Asset Management Group plc lifted its holdings in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after buying an additional 157,809 shares during the period. QRG Capital Management Inc. lifted its stake in shares of IQVIA by 2.1% in the third quarter. QRG Capital Management Inc. now owns 6,190 shares of the medical research company’s stock worth $1,467,000 after acquiring an additional 130 shares during the period. Asset Management One Co. Ltd. boosted its holdings in IQVIA by 1.3% in the third quarter. Asset Management One Co. Ltd. now owns 71,077 shares of the medical research company’s stock valued at $16,843,000 after acquiring an additional 888 shares during the last quarter. National Pension Service increased its position in IQVIA by 12.7% during the 3rd quarter. National Pension Service now owns 435,067 shares of the medical research company’s stock valued at $103,098,000 after purchasing an additional 49,130 shares during the period. Finally, Intact Investment Management Inc. raised its holdings in IQVIA by 21.8% during the 3rd quarter. Intact Investment Management Inc. now owns 3,180 shares of the medical research company’s stock worth $754,000 after purchasing an additional 570 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IQV shares. Evercore ISI decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. JPMorgan Chase & Co. decreased their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Stock Performance

Shares of IQV opened at $221.19 on Thursday. IQVIA Holdings Inc. has a 52 week low of $190.20 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a 50 day moving average price of $232.31 and a two-hundred day moving average price of $229.48. The firm has a market capitalization of $40.15 billion, a P/E ratio of 29.03, a P/E/G ratio of 2.15 and a beta of 1.51.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.